Clinical trial · Interventional
Feasibility of Combined Genomics/Transcriptomics for Patients With Lymphoma
NCT05464823CI-TRIAL-00122056active not recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To learn more about the usefulness of molecular testing with the Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Molecular Functional Portrait | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Molecular Testing
- description
- Molecular Functional (MF) Portrait (a commercial test conducted by the sponsor of this study, BostonGene) in guiding lymphoma care.
- interventionNames
- Other: Molecular Functional Portrait
Primary outcomes (1)
- measure
- Percentage of participants who have genomic test results available in <=7 days
- timeFrame
- through study completion an average of 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Patient Eligibility: Inclusion Criteria: 1. Male/female patients who are at least 18 years of age on the day of informed consent signing. 2. Patients must have a histologically documented diffuse large B-cell lymphoma requiring therapy. 3. Provision of written informed consent for the study. Exclusion Criteria: 1\. None
References
Publications (0)
Data not yet available
No reference posted for this study.